M&A, IPOs and VC raises: Biotech, medtech execs look to 2019 by Amirah Al Idrus, Conor Hale, Ben Adams Friday, January 11, 2019 What can you expect from M&A, IPOs and VC raises in 2019? We spoke to execs at the J.P. Morgan Healthcare Conference this week to find out.
Guardant unveils epigenetic research test for early-stage cancer by Conor Hale Tuesday, January 8, 2019 SAN FRANCISCO—Guardant Health has launched a new epigenetic liquid biopsy test for researchers aimed at spotting cancer in its early stages.
Guardant to develop blood tests for AstraZeneca’s targeted drugs by Conor Hale Friday, December 14, 2018 AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi.
Guardant Health discloses cyberattack alongside planned IPO by Conor Hale Monday, September 10, 2018 In its IPO filing, Guardant Health disclosed it had received a cyberattack, with hackers accessing the personal information of about 1,100 patients.
Blood tester Guardant Health files for IPO by Conor Hale Thursday, September 6, 2018 Cancer blood test maker Guardant Health plans to go public, filing an IPO on the Nasdaq using the symbol GH.
SoftBank mulling $150M investment in Science 37: report by Conor Hale Wednesday, June 6, 2018 SoftBank is considering a $150 million investment in siteless trial runner Science 37, the latest in a string of biotech deals, according to reports.
FierceMedTech’s 2017 Fierce 15 by Amirah Al Idrus Monday, December 11, 2017 Genomics, bioelectronics and artificial intelligence are clear themes among FierceMedTech's 2017 Fierce 15 companies.
Guardant sues Foundation Medicine over false advertising by Amirah Al Idrus Friday, June 23, 2017 Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition.
